Eric Mcdade Do

List of Publications by Year
in descending order

74 papers	6,914 citations	201674 27 h-index	155660 55 g-index
84 all docs	84 docs citations	84 times ranked	8827 citing authors

#	Article	IF	Citations
1	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. New England Journal of Medicine, 2012, 367, 795-804.	27.0	3,005
2	Symptom onset in autosomal dominant Alzheimer disease. Neurology, 2014, 83, 253-260.	1.1	391
3	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurology, The, 2018, 17, 241-250.	10.2	383
4	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. Annals of Neurology, 2016, 79, 929-939.	5.3	381
5	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2020, 26, 398-407.	30.7	351
6	Regional variability of imaging biomarkers in autosomal dominant Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4502-9.	7.1	309
7	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology, 2018, 91, e1295-e1306.	1.1	193
8	Stop Alzheimerâ€™s before it starts. Nature, 2017, 547, 153-155.	27.8	189
9	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2021, 27, 1187-1196.	30.7	182
10	Developing an international network for Alzheimerâ€™s research: the Dominantly Inherited Alzheimer Network. Clinical Investigation, 2012, 2, 975-984.	0.0	180
11	Neurological manifestations of autosomal dominant familial Alzheimerâ€™s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurology, The, 2016, 15, 1317-1325.	10.2	87
12	Comparison of Pittsburgh compound B and florbetapir in crossâ€sectional and longitudinal studies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 180-190.	2.4	84
13	Preferential degradation of cognitive networks differentiates Alzheimerâ€™s disease from ageing. Brain, 2018, 141, 1486-1500.	7.6	79
14	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. Lancet Neurology, The, 2022, 21, 329-341.	10.2	72
15	BDNFVal66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimerâ€™s disease. Brain, 2016, 139, 2766-2777.	7.6	70
16	Early behavioural changes in familial Alzheimerâ€™s disease in the Dominantly Inherited Alzheimer Network. Brain, 2015, 138, 1036-1045.	7.6	67
17	The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nature Reviews Neurology, 2021, 17, 703-714.	10.1	65
18	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 614-628.	7.9	61

#	Article	IF	Citations
19	Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from lateâ€onset amyloid deposition. Alzheimer's and Dementia, 2018, 14, 743-750.	0.8	51
20	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1427-1437.	0.8	51
21	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimerâ€™s disease. PLoS ONE, 2018, 13, e0195838.	2.5	51
22	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimerâ€™s Disease: Results from the DIAN Study Group. PLoS ONE, 2016, 11, e0152082.	2.5	45
23	The informed road map to prevention of Alzheimer Disease: A call to arms. Molecular Neurodegeneration, 2021, 16, 49.	10.8	43
24	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 1225.	3.3	42
25	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: AÂserial magnetic resonance imaging study. Alzheimer's and Dementia, 2018, 14, 43-53.	0.8	42
26	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimerâ€™s disease. Brain, 2019, 142, 1429-1440.	7.6	36
27	Variant-dependent heterogeneity in amyloid Î² burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurology, The, 2022, 21, 140-152.	10.2	34
28	Discovery and validation of autosomal dominant Alzheimerâ€™s disease mutations. Alzheimer's Research and Therapy, 2018, 10, 67.	6.2	29
29	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology, 2015, 85, 790-798.	1.1	27
30	Seizures as an early symptom of autosomal dominant Alzheimer's disease. Neurobiology of Aging, 2019, 76, 18-23.	3.1	27
31	Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease. Annals of Neurology, 2018, 84, 424-435.	5.3	25
32	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. JAMA Network Open, 2019, 2, e1917126.	5.9	23
33	Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology. Brain, 2022, 145, 3594-3607.	7.6	20
34	A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, 1330-1337.	0.8	19
35	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connectivity, 2021, 11, 239-249.	1.7	18
36	Tau Positron Emission Tomography in Autosomal Dominant Alzheimer Disease. JAMA Neurology, 2018, 75, 536.	9.0	17

#	Article	IF	Citations
37	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology, 2021, 96, e1632-e1645.	1.1	16
38	Comparing amyloid-Î² plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. Acta Neuropathologica, 2021, 142, 689-706.	7.7	15
39	Association ofBDNFVal66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. JAMA Neurology, 2022, 79, 261.	9.0	15
40	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 669-677.	2.4	14
41	Dominantly inherited Alzheimer's disease in Latin America: Genetic heterogeneity and clinical phenotypes. Alzheimer's and Dementia, 2021, 17, 653-664.	0.8	14
42	The association between pulse pressure change and cognition in late life: Age and where you start matters. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 56-66.	2.4	13
43	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2020, 16, 219-228.	0.8	13
44	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 2022, 18, 2687-2698.	0.8	13
45	Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 413-420.	2.4	9
46	Thatâ€™s Inappropriate! Social Norms in an Older Population-based Cohort. Alzheimer Disease and Associated Disorders, 2018, 32, 150-155.	1.3	8
47	Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials. Journal of the American Geriatrics Society, 2019, 67, 845-847.	2.6	4
48	Different rates of cognitive decline in autosomal dominant and lateâ€onset Alzheimer disease. Alzheimer's and Dementia, 2022, 18, 1754-1764.	0.8	4
49	Avoid or Embrace? Practice Effects in Alzheimerâ€™s Disease Prevention Trials. Frontiers in Aging Neuroscience, 0, 14, .	3.4	3
50	[F3â€“01â€“04]: LONGITUDINAL BIOMARKER CHANGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P879.	0.8	2
51	P1â€023: MASS SPECTROMETRYâ€“BASED MEASUREMENT OF LONGITUDINAL CSF TAU IDENTIFIES DIFFERENT PHOSPHORYLATED SITES THAT TRACK DISTINCT STAGES OF PRESYMPTOMATIC DOMINANTLY INHERITED AD. Alzheimer's and Dementia, 2018, 14, P273.	0.8	2
52	Twoâ€period linear mixed effects models to analyze clinical trials with runâ€in data when the primary outcome is continuous: Applications to Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 450-457.	3.7	2
53	Reply to: Major Clinical Trials Failed the Amyloid Hypothesis of Alzheimer's Disease. Journal of the American Geriatrics Society, 2019, 67, 848-849.	2.6	2
54	Resilience at High Resolution. Neurology, 2022, 98, 519-520.	1.1	2

#	Article	IF	Citations
55	Biomarker clustering in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 274-284.	0.8	2
56	Functional exploration of AGFG2, a novel player in the pathology of Alzheimer disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e054240.	0.8	1
57	P1-247: BINDING OF PITTSBURGH COMPOUND B TO BOTH NORMAL AND ABNORMAL WHITE MATTER IN ELDERLY COGNITIVELY NORMAL CONTROLS. , 2014, 10, P396-P397.		0
58	P4â€004: Planning Dose Escalation in Phase III Clinical Trials May Prevent Underpowered Trials and Mitigate the Increase in Sample Size or Duration of Adaptive Trials. Alzheimer's and Dementia, 2016, 12, P1015.	0.8	0
59	O3-09-05: The Dian-Nacc UDS Comparison Study: Rates of Cognitive Decline. , 2016, 12, P309-P309.		0
60	F4â€03â€02: The Dominantly Inherited Alzheimer Network Trials Unit. Alzheimer's and Dementia, 2016, 12, P326.	0.8	0
61	O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network. , 2016, 12, P378-P379.		0
62	[ICâ€Pâ€057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P47.	0.8	0
63	[P2â€“372]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P768.	0.8	0
64	[ICâ€Pâ€054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P44.	0.8	0
65	[ICâ€Pâ€166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P125.	0.8	0
66	[O1â€“02â€“03]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
67	[O1â€“02â€“04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
68	O3â€13â€03: THE RELATIONSHIP BETWEEN TAU PET AND OTHER AD BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P1056.	0.8	0
69	O2â€04â€03: WHAT GOES UP MUST COME DOWN: LONGITUDINAL DECLINE IN CEREBROSPINAL FLUID TAU PEPTIDES IS ASSOCIATED WITH PROGRESSIVE CORTICAL ATROPHY. Alzheimer's and Dementia, 2018, 14, P622.	0.8	0
70	ICâ€02â€01: THE RELATIONSHIP BETWEEN TAU PET AND AGE ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2018, 14, P1.	0.8	0
71	P2â€362: THE RELATIONSHIP BETWEEN TAU PET AND AGE ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2018, 14, P829.	0.8	0
72	ICâ€04â€02: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CORTICAL THICKNESS, BETAâ€AMYLOID BURDEN, AND CEREBRAL GLUCOSE METABOLISM IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P7.	0.8	0

#	Article	IF	Citations
73	Targeting Alzheimer's Disease in the Preclinical Stage. , 2019, 15, 602-603.		0
74	ICâ€Pâ€098: PHOSPHORYLATION OF SPECIFIC TAU SITES IS ASSOCIATED WITH LOSS OF WHITE MATTER INTEGRITY IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2019, 15, P85.	0.8	0